At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
BHVN Biohaven Pharmaceutical Holding Co Ltd.
Post-Mkt 09-21 18:34:29 EDT
14.22
+0.60
+4.41%
盘后14.19
-0.03-0.21%
17:41 EDT
High14.49Low13.56Vol3.29M
Open13.90D1 Closing13.62Amplitude6.86%
Mkt Cap2.14BTradable Cap1.68BTotal Shares150.42M
T/O46.41MT/O Rate2.79%Tradable Shares117.99M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Biohaven's Kv7 Program Remains Key Stock Driver, UBS Says
MT Newswires Live  ·  09-18
Biohaven's Kv7 Program Remains Key Stock Driver, UBS Says
Xenon Stock Craters on Drug Trial Setback. Its Failure Could be This Rival's Gain.
Dow Jones  ·  09-18
Xenon Stock Craters on Drug Trial Setback. Its Failure Could be This Rival's Gain.
Biohaven Stock is Sinking. Epilepsy Drug Trial Roadblock is Only the Latest Blow.
Dow Jones  ·  09-11
Biohaven Stock is Sinking. Epilepsy Drug Trial Roadblock is Only the Latest Blow.
Biohaven Price Target Maintained with a $10.00/Share by HC Wainwright & Co.
Dow Jones  ·  09-11
Biohaven Price Target Maintained with a $10.00/Share by HC Wainwright & Co.
Biohaven clinical hold adds level of uncertainty, says H.C. Wainwright
TIPRANKS  ·  09-11
Biohaven clinical hold adds level of uncertainty, says H.C. Wainwright
Impact of Biohaven’s partial FDA hold ‘manageable,’ says Raymond James
TIPRANKS  ·  09-10
Impact of Biohaven’s partial FDA hold ‘manageable,’ says Raymond James
Biohaven falls -15.3%
TIPRANKS  ·  09-10
Biohaven falls -15.3%
U.S. Stocks on the MOVE-Lovesac, Hagerty, Biohaven
Reuters  ·  09-10
U.S. Stocks on the MOVE-Lovesac, Hagerty, Biohaven
Biohaven Drops as US FDA Seeks More BHV-7000 Safety Data
Reuters  ·  09-10
Biohaven Drops as US FDA Seeks More BHV-7000 Safety Data
Top Premarket Decliners
MT Newswires Live  ·  09-10
Top Premarket Decliners
Biohaven Shares Down 9.1% Premarket After US FDA Places Partial Clinical Hold on Co's Epilepsy Drug Trial
THOMSON REUTERS  ·  09-10
Biohaven Shares Down 9.1% Premarket After US FDA Places Partial Clinical Hold on Co's Epilepsy Drug Trial
Biohaven - Dosing Continues for over 600 Randomized Patients in Bhv-7000 Program - SEC Filing
THOMSON REUTERS  ·  09-10
Biohaven - Dosing Continues for over 600 Randomized Patients in Bhv-7000 Program - SEC Filing
Biohaven - FDA Issues Partial Clinical Hold Pausing New Enrollment for Bhv-7000 on Sept 4, 2026 - SEC Filing
THOMSON REUTERS  ·  09-10
Biohaven - FDA Issues Partial Clinical Hold Pausing New Enrollment for Bhv-7000 on Sept 4, 2026 - SEC Filing
FDA Places Partial Clinical Hold on Biohaven BHV-7000 Epilepsy Trial, Halting New Enrollment
Reuters  ·  09-10
FDA Places Partial Clinical Hold on Biohaven BHV-7000 Epilepsy Trial, Halting New Enrollment
U.S. Stocks on the MOVE-Best Buy, Peloton, Apple
Reuters  ·  09-09
U.S. Stocks on the MOVE-Best Buy, Peloton, Apple
Biohaven Stock Seen Range-Bound as Near-Term Catalysts Fade, RBC Says
MT Newswires Live  ·  09-09
Biohaven Stock Seen Range-Bound as Near-Term Catalysts Fade, RBC Says
U.S. Stocks on the MOVE-Sigma Lithium, Shake Shack, Novartis
Reuters  ·  09-08
U.S. Stocks on the MOVE-Sigma Lithium, Shake Shack, Novartis
RBC Downgrades Biohaven to Sector Perform From Outperform, Cuts Price Target to $19 From $23, Keeps Speculative Risk
MT Newswires Live  ·  09-08
RBC Downgrades Biohaven to Sector Perform From Outperform, Cuts Price Target to $19 From $23, Keeps Speculative Risk
RBC Downgrades Biohaven to 'sector Perform', Shares Fall
Reuters  ·  09-08
RBC Downgrades Biohaven to 'sector Perform', Shares Fall
Biohaven Ltd. : RBC Cuts to Sector Perform from Outperform; Cuts Target Price to $19 from $23
THOMSON REUTERS  ·  09-08
Biohaven Ltd. : RBC Cuts to Sector Perform from Outperform; Cuts Target Price to $19 from $23

Introduction

Company Name.
Biohaven Pharmaceutical Holding Co Ltd.
Affiliated Markets:
NYSE
Listing Date:
--
Main Business:
Biohaven Ltd., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with debilitating neurological and neuropsychiatric diseases in the United States. The company's pipeline products include BHV-7000, a potassium channel activator for the treatment of focal epilepsy; BHV-7010, a Kv7 channel modulator for the treatment of different neurological diseases; Troriluzole, a tripeptide prodrug that is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500, a low-trapping glutamate N-methyl-D-aspartate receptor antagonist for neuropathic pain; and Verdiperstat, an oral myeloperoxidase inhibitor, which is in Phase 3 clinical trial for the treatment of neurodegenerative diseases. It also offers Taldefgrobep Alfa, an anti-myostatin adnectin, which is in Phase 3 clinical trial for the treatment of spinal muscle atrophy; and BHV-1100 that is in Phase 1a/1b clinical trial for multiple myeloma patients. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut. Biohaven Ltd. is a subsidiary of Biohaven Pharmaceutical Holding Company Ltd.
Issue price:
--